Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study

BMC Public Health

Kathy M Rose³  Randi E Foraker²  Joseph P Kitzmiller¹ 

[1] Departments of Pharmacology and Biomedical Engineering, The Ohio State University Medical Center, 5072B Graves Hall 333 West 10th Avenue, Columbus, OH, 43210, USA;Division of Epidemiology, College of Public Health, The Ohio State University, 334 Cunz Hall, 1841 Neil Avenue, Columbus, OH, 43230, USA;SRA International, Inc, 2605 Meridian Parkway, Durham, NC, 27713, USA

关键词: Cardiovascular disease;    Lipid-lowering pharmacotherapy;    Statins;    Socioeconomics;    Lipids;   

Others  :  1162193
DOI  :  10.1186/1471-2458-13-488

 received in 2012-12-02, accepted in 2013-05-16,  发布年份 2013

【 摘 要 】

Background

Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and the prescribing and use of lipid-lowering agents have been reported in several developed countries.

Methods

We evaluated the association of census tract-level neighborhood household income (nINC) and lipid-lowering medications received during hospitalization or at discharge among 3,546 (5,335 weighted) myocardial infarction (MI) events in the United States (US) Atherosclerosis Risk In Communities (ARIC) surveillance study (1999–2002). Models included neighborhood household income, race, gender, age, study community, year of MI, hospital type (teaching vs. nonteaching), current or past history of hypertension, diabetes or heart failure, and presence of cardiac pain.

Results

About fifty-nine percent of patients received lipid-lowering pharmacotherapy during hospitalization or at discharge. Low nINC was associated with a lower likelihood (prevalence ratio 0.89, 95% confidence interval: 0.79, 1.01) of receiving lipid-lowering pharmacotherapy compared to high neighborhood household income, and no significant change in this association resulted when adjusted for the above-mentioned covariates.

Conclusion

Patient’s socioeconomic status appeared to influence whether they were prescribed a lipid-lowering pharmacotherapy after hospitalization for myocardial infarction in the US ARIC surveillance study (1999–2002).

【 授权许可】

   
2013 Kitzmiller et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ward PR, Noyce PR, Leger AS: How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in north west England. Int J Equity Health 2007, 6:2. BioMed Central Full Text
• [2]Thomson RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sorensen HT: Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005, 60:534-542.
• [3]Stocks N, Ryan P, McElroy H, Allan J: Statin prescribing in Australia: socioeconomic and sex differences. Med J Australia 2004, 180:229-231.
• [4]Litaker D, Koroukian S, Frolkis JP, Aron DC: Disparities among the disadvantaged: Variation in lipid management in the Ohio Medicaid Program. Preventative Med 2006, 42:313-315.
• [5]Foraker RE, Rose KM, Whitsel EA, Suchindran CM, Wood JL, Rosamond WD: Neighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance. BMC Public Health 2010, 10:632. BioMed Central Full Text
• [6]The ARIC investigators: The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989, 4:687-702.
• [7]Bryk A, Raudenbush A: Hierarchical linear models: applications and data analysis methods. Newbury Park, CA: Sage Publications; 1992.
• [8]Williams RL: A note on robust variance estimation for cluster-correlated data. Biometrics 2000, 56:645-646.
• [9]Foraker RE, Rose KM, Kucharsska-Newton AM, Ni H, Suchindran CM, Whitsel EA: Variation in rates of fatal coronary heart disease by neighborhood socioeconomic status: the atherosclerosis risk in communities surveillance (1992–2002). Ann Epidemiol 2011, 21(8):580-588.